Share on StockTwits

Cepheid (NASDAQ:CPHD) EVP Kerry Flom sold 1,282 shares of the stock on the open market in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $48.97, for a total transaction of $62,779.54. Following the completion of the sale, the executive vice president now directly owns 989 shares in the company, valued at approximately $48,431. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Cepheid (NASDAQ:CPHD) traded down 2.80% on Monday, hitting $47.89. 337,460 shares of the company’s stock traded hands. Cepheid has a 52 week low of $30.95 and a 52 week high of $55.89. The stock’s 50-day moving average is $45.63 and its 200-day moving average is $47.93. The company’s market cap is $3.339 billion.

Cepheid (NASDAQ:CPHD) last released its earnings data on Thursday, April 17th. The company reported ($0.01) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.17) by $0.16. The company had revenue of $106.90 million for the quarter, compared to the consensus estimate of $104.90 million. During the same quarter last year, the company posted $0.11 earnings per share. Cepheid’s revenue was up 16.3% compared to the same quarter last year. On average, analysts predict that Cepheid will post $-0.34 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Craig Hallum upgraded shares of Cepheid from a “sell” rating to a “hold” rating in a research note on Monday, June 9th. Separately, analysts at SunTrust reiterated a “neutral” rating on shares of Cepheid in a research note on Monday, June 9th. They now have a $49.00 price target on the stock, down previously from $54.00. Finally, analysts at Needham & Company LLC upgraded shares of Cepheid from a “hold” rating to a “buy” rating in a research note on Tuesday, May 27th. They now have a $50.00 price target on the stock. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $52.00.

Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.